title: Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma.
abstract: We report that 38% of primary large B-cell lymphoma (DLBCL) tested expressed active Src family kinases, which are targeted by dasatinib. The expression of active Src family of kinases (SFK) in primary DLBCL tumors correlated with unfavorable prognostic markers such as Ki67 and Mum1. Using four DLBCL cell lines we found that: (1) sensitivity to dasatinib (but not imatinib) varied 400-fold; (2) dasatinib resistance was associated with distinct signaling profiles downstream of BCR activation. In particular, although Src family kinase phosphorylation was inhibited by 100-150 nM dasatinib in all cell lines, this failed to inhibit BCR-mediated Blnk phosphorylation, calcium signaling and proliferation in a dasatinib resistant cell line.
authors.affiliation: Sir Mortimer B Davis-Jewish General Hospital, Montreal Centre for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.
authors.forename: C Annette
authors.initials: CA
authors.lastname: Hollmann
authors.forename: Alexandar
authors.initials: A
authors.lastname: Tzankov
authors.forename: Verónica L
authors.initials: VL
authors.lastname: Martínez-Marignac
authors.forename: Kristi
authors.initials: K
authors.lastname: Baker
authors.forename: Czeslawa
authors.initials: C
authors.lastname: Grygorczyk
authors.forename: Ryszard
authors.initials: R
authors.lastname: Grygorczyk
authors.forename: William
authors.initials: W
authors.lastname: Foulkes
authors.forename: Jay
authors.initials: J
authors.lastname: Nadeau
authors.forename: Stephan
authors.initials: S
authors.lastname: Dirnhofer
authors.forename: Raquel
authors.initials: R
authors.lastname: Aloyz
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D001549:Benzamides; D015153:Blotting, Western; D020013:Calcium Signaling / Q000187:drug effects / Q000502:physiology*; D045744:Cell Line, Tumor; D002469:Cell Separation; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D004789:Enzyme Activation; D005434:Flow Cytometry; D006801:Humans; D000068877:Imatinib Mesylate; D007150:Immunohistochemistry; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics / Q000378:metabolism*; D008856:Microscopy, Fluorescence; D010879:Piperazines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013844:Thiazoles / Q000494:pharmacology; D046888:Tissue Array Analysis; D019061:src-Family Kinases / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D019061:src-Family Kinases; D000069439:Dasatinib